Thrombocytopenia acquiredD69.5

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 19.03.2023

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Acquired platelet deficiency.

ClassificationThis section has been translated automatically.

Depending on the etiology, a distinction is made between:

  • Amegakaryocytic thrombocytopenia: Formation disorder of the thrombocytes, e.g. in case of drug-induced bone marrow insufficiency, malignancies of the bone marrow, vitamin B12 or folic acid deficiency, toxic or infectious bone marrow damage, osteomyelosclerosis.
  • Megakaryocytic thrombocytopenia: Shortened platelet life span: Frequent allergic (drug!) induced platelet destruction. The thrombocytopenias observed after COVID vaccinations are likely to be in this category (Gambichler T et al 2022).
  • Essential thrombocytopenia: Idiopathic thrombocytopenic purpura.

LiteratureThis section has been translated automatically.

  1. Gambichler T et al. (2022) Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol 36:172-180.

  2. Schulz C, Kaufmann R, Ochsendorf F (2006) Generalized purpura as dermatologic manifestation of thrombcytopenia. Dermatologist 57: 697-700

Authors

Last updated on: 19.03.2023

Author: Prof. Dr. med. Peter Altmeyer